Erin Haskin
Family · Thomasville, GANPI 1235747221
Payments from drug & device makers
Across 110 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$431
- Lilly USA, LLC$281
- AstraZeneca$153
- Regeneron Healthcare Solutions, Inc.$140
- Amgen$133
- LEO Pharma Inc.$121
- plus $858 from 26 others
What the payments were for
- Food & beverage$2,118100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $431 |
| Lilly USA, LLC | 14 | $281 |
| AstraZeneca | 8 | $153 |
| Regeneron Healthcare Solutions, Inc. | 7 | $140 |
| Amgen | 9 | $133 |
| LEO Pharma Inc. | 5 | $121 |
| Medtronic | 5 | $106 |
| Pfizer | 4 | $72 |
| Seqirus USA Inc | 4 | $72 |
| Boehringer Ingelheim | 3 | $59 |
| Merck | 4 | $57 |
| Bayer | 3 | $56 |
| Xeris Pharmaceuticals, Inc. | 2 | $48 |
| Novartis | 2 | $44 |
| Dexcom, Inc. | 1 | $33 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Verona Pharma, Inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Incyte Corporation | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Inogen, Inc. | 2 | $16 |
| United Therapeutics Corporation | 1 | $16 |
| Fresenius Kabi USA, LLC | 1 | $15 |
| AbbVie | 1 | $14 |
| Inari Medical, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 2 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$123
How this compares
$2,118 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 269 | $272,837 |
| MounjaroTirzepatide | 202 | $207,737 |
| Tresiba Flextouch U-200Insulin Degludec | 102 | $142,744 |
| FarxigaDapagliflozin Propanediol | 115 | $94,852 |
| TrulicityDulaglutide | 86 | $91,128 |
| JardianceEmpagliflozin | 95 | $68,867 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $36,510 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 35 | $25,411 |
| JanuviaSitagliptin Phosphate | 36 | $23,403 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $23,363 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 16 | $17,479 |
| RybelsusSemaglutide | 15 | $16,144 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 108 | $15,521 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $7,930 |
| Humalog Kwikpen U-100Insulin Lispro | 25 | $5,063 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $281 | $302,189313 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $431 | $290,681295 claims |
| AstraZenecaFarxiga | $153 | $94,852115 claims |
| Boehringer IngelheimJardiance | $59 | $68,86795 claims |
| MerckJanuvia | $57 | $23,40336 claims |
| Sanofi-aventis U.S. LLCLantus | $19 | $3,34826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.
Other family in Thomasville
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.